pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,639 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT834Endpoints640BioPharma Dive243onclive165BioSpace98Fierce Biotech96raps39globenewswire health28fda recalls
therapy area
allOncology5005Rare Disease851Cardiology802Hematology772Immunology733Psychiatry & CNS582Pulmonology571Vaccines
  • ‘Forever chemicals’ in baby formula? Scientists unpack FDA results
    FDA review confirmed overall safety of 16 brands of baby formula. In a STAT Q&A, experts unpack what low-level PFAS findings mean to worried moms.
    STAT · 3mo ago↗ source
  • Opinion: The psychedelic revolution is leaving behind people of color
    Psychedelics’ potential as a form of treatment is virtually unmatched. But their promise faces both scientific uncertainty and thorny political questions.
    STAT · 3mo ago↗ source
  • STAT+: OxyContin maker Purdue Pharma set to dissolve after judge approves its criminal sentence
    At the hearing, the judge heard from mothers who lost sons to overdose, a teenager born into withdrawal, and people who spent years dealing with addiction treatment.
    STAT
← prev
page 60 of 66
next →
23
fda press21
fda medwatch18
517
Endocrinology & Metabolism293
Ophthalmology258
Infectious Disease253
Nephrology239
· 3mo ago
↗ source
  • Remembering J. Craig Venter: a relentless scientist who changed biotech — and was all too easily misunderstood
    J. Craig Venter, the scientist whose relentless ambition helped turn genetics from an artisanal trade into an industrialized information machine, died at 79.
    STAT · 3mo ago↗ source
  • STAT+: Katherine Szarama named acting director of FDA’s vaccines and biologics center
    Katherine Szarama, who joined the FDA last year to serve as Vinay Prasad’s deputy, will now fill his shoes at CBER.
    STAT · 3mo ago↗ source
  • STAT+: In her own words: Surgeon general nominee Nicole Saphier expresses enthusiasm and caution for MAHA
    Examining the past statements and writings of Trump's third surgeon general nominee, Dr. Nicole Saphier, on vaccines, autism, peptides, diet and more.
    STAT · 3mo ago↗ source
  • STAT+: Hair-raising trial results, and Servier’s M&A wishlist
    Why are investors excited about hair loss drugs? Will AI make clinical trials run more smoothly? And more in "The Readout LOUD," STAT's weekly biotech podcast.
    STAT · 3mo ago↗ source
  • FDA's oncology advisors vote against 'new paradigm' in AstraZeneca trial
    In its first meeting in about nine months, the FDA’s advisory committee of oncology experts voted 6-3 Thursday that a late-stage trial for AstraZeneca’s oral SERD camizestrant didn't show a “clinic…
    Endpoints · 3mo ago↗ source
  • Krazati fails confirmatory trial in colorectal cancer, putting approval at risk
    Bristol Myers Squibb’s cancer drug Krazati has failed its confirmatory study in second-line colorectal cancer, a company spokesperson confirmed to Endpoints News. Krazati had received accelerated a…
    Endpoints · 3mo ago↗ source
  • House panel calls to ban China data from FDA drug trial applications
    A powerful spending committee in Congress wants the FDA to ban the use of clinical trial data from China in future applications by drugmakers to test new treatments. The language was
    Endpoints · 3mo ago↗ source
  • Court dismisses part of Lilly lawsuit against Empower, some claims can proceed
    A federal judge has dismissed part of Eli Lilly’s lawsuit alleging Empower Pharmacy misled customers about its compounded versions of the obesity drug tirzepatide. But the court said some of Lilly’…
    Endpoints · 3mo ago↗ source
  • Supreme Court questions how far generics makers can go with 'skinny label' drugs
    WASHINGTON — Supreme Court justices gave a few hints about how they intend to rule in a divisive case for the pharmaceutical industry. In its final argument scheduled for this term, the high court…
    Endpoints · 3mo ago↗ source
  • STAT+: As artificial intelligence shows off diagnostic chops, scientists reckon with the way forward
    On Thursday, researchers published in Science the results of a study that tested an OpenAI model on diagnostic and clinical reasoning tasks.
    STAT · 3mo ago↗ source
  • Trump drops Casey Means as surgeon general nominee, opts for radiologist Nicole Saphier
    Trump slammed Sen. Bill Cassidy for blocking his surgeon general pick, as he nominated a replacement.
    STAT · 3mo ago↗ source
  • STAT+: FDA wants to exclude weight loss drugs from a compounding list
    FDA moves to remove semaglutide, tirzepatide, and liraglutide from its 503B compounding list, saying there's no shortage of GLP-1 drugs from Novo Nordisk and Eli Lilly.
    STAT · 3mo ago↗ source
  • STAT+: Five-way obesity drug is super effective — in mice
    A 'quintuple agonist,' Alector halts it Alzheimer's trial, and more biotech news from The Readout
    STAT · 3mo ago↗ source
  • STAT+: DOJ, Elevance spar over access to top exec in Medicare Advantage fraud case
    Elevance said a top exec would depart, days after the Justice Department asked to depose him.
    STAT · 3mo ago↗ source
  • Avalyn's upsized IPO; Alector ends another study in GSK partnership
    🔔 Avalyn Pharma’s $300M IPO: The Boston, MA-based biotech is selling over 16.5 million shares at $18 apiece. The company is set to start trading as {$AVLN} on the Nasdaq Thursday ...
    Endpoints · 3mo ago↗ source
  • Analysts focus on three programs in big year for Bristol Myers
    Wall Street’s expectations for Bristol Myers Squibb’s upcoming slate of data readouts are reaching a fever pitch. Analysts lobbed questions regarding at least half a dozen trial results expected by…
    Endpoints · 3mo ago↗ source
  • STAT+: Hinge has a new FDA-cleared migraine device
    In this edition of STAT Health Tech: FDA's plan to use AI to speed up trials, Hinge's new migraine device, and boosting cancer screening with texts.
    STAT · 3mo ago↗ source
  • XTL Bio to acquire psychedelic biotech; WuXi AppTec’s Q1 revenue rise
    Plus, news about PCI Pharma: 🏭 XTL Bio steps into psychedelics: XTL Biopharmaceuticals is acquiring 100% of the outstanding shares of psychedelic-focused biotech Psyga Bio. XTL will gain Psyga’s m…
    Endpoints · 3mo ago↗ source
  • STAT+: Cigna will exit ACA individual markets next year, adding to tumult for patients
    ACA membership is tumbling after Congress failed to extend extra subsidies that helped people afford the coverage.
    STAT · 3mo ago↗ source
  • STAT+: Democrats go hard on health care affordability
    The Senate's top Democrat unveiled a health policy outline that calls for lowering patients' costs across the board.
    STAT · 3mo ago↗ source
  • What we heard at a health tech conference in Boston
    I just came back from the Digital Healthcare Innovation Summit in Boston earlier this week, where I got a good look into what investors are thinking about. A few impressions: Investors see a ...
    Endpoints · 3mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about a Supreme Court hearing on ‘skinny labels,’ AstraZeneca U.K. expansion, and more
    AstraZeneca will resume expansion of its U.K. R&D operations after the trade deal with the U.S. included measures to lift U.K. drug spending
    STAT · 3mo ago↗ source